BIOMAT Database Logo BIOMAT Database Logo

Effectiveness of pergolide in hyperprolactinaemia. 1983

A J Isaacs

UI MeSH Term Description Entries
D010479 Pergolide A long-acting dopamine agonist which has been used to treat PARKINSON DISEASE and HYPERPROLACTINEMIA but withdrawn from some markets due to potential for HEART VALVE DISEASES. Celance,LY-127,809,LY-127809,Parkotil,Pergolide Mesylate,Permax,Pharken,LY127,809,LY127809,Mesylate, Pergolide
D011388 Prolactin A lactogenic hormone secreted by the adenohypophysis (PITUITARY GLAND, ANTERIOR). It is a polypeptide of approximately 23 kD. Besides its major action on lactation, in some species prolactin exerts effects on reproduction, maternal behavior, fat metabolism, immunomodulation and osmoregulation. Prolactin receptors are present in the mammary gland, hypothalamus, liver, ovary, testis, and prostate. Lactogenic Hormone, Pituitary,Mammotropic Hormone, Pituitary,Mammotropin,PRL (Prolactin),Hormone, Pituitary Lactogenic,Hormone, Pituitary Mammotropic,Pituitary Lactogenic Hormone,Pituitary Mammotropic Hormone
D004873 Ergolines A series of structurally-related alkaloids that contain the ergoline backbone structure. Ergoline
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D000978 Antiparkinson Agents Agents used in the treatment of Parkinson's disease. The most commonly used drugs act on the dopaminergic system in the striatum and basal ganglia or are centrally acting muscarinic antagonists. Antiparkinson Drugs,Antiparkinsonian Agents,Antiparkinsonians,Agents, Antiparkinson,Agents, Antiparkinsonian,Drugs, Antiparkinson

Related Publications

A J Isaacs
Effectiveness of pergolide mesylate in long term treatment of hyperprolactinaemia.
April 1983, British medical journal (Clinical research ed.),
A J Isaacs
The long-acting dopamine agonist pergolide mesylate for treatment of hyperprolactinaemia.
January 1984, Acta Europaea fertilitatis,
A J Isaacs
Comparison of the clinical activity of mesulergine and pergolide in the treatment of hyperprolactinaemia.
May 1985, Clinical endocrinology,
A J Isaacs
Treatment of hyperprolactinaemia with pergolide mesylate: acute effects and preliminary evaluation of long-term treatment.
September 1981, Lancet (London, England),
A J Isaacs
Microbial transformations of pergolide to pergolide sulfoxide and pergolide sulfone.
July 1983, Journal of pharmaceutical sciences,
A J Isaacs
Hyperprolactinaemia does not always mean 'hyperprolactinaemia'!
February 2005, European journal of obstetrics, gynecology, and reproductive biology,
A J Isaacs
Hyperprolactinaemia.
January 1989, BMJ (Clinical research ed.),
A J Isaacs
Hyperprolactinaemia.
December 2017, Australian prescriber,
A J Isaacs
Hyperprolactinaemia.
December 2019, Journal of clinical medicine,
A J Isaacs
Hyperprolactinaemia.
November 1988, BMJ (Clinical research ed.),
Copied contents to your clipboard!